In controlled clinical studies involving approximately 1,400 patients, the following adverse reactions have been reported in patients treated with<unk> . When reporting to the very common (≥ 1 / 10), common (≥ 1 / 100, 51/10), uncommon (≥ 1 / 1000, 51/100), rare (≥ 1/10.000, 51/1000) and distinction very rarely (51/10.000), including individual cases: * Investigations Common: serum triglyceride increased; Uncommon: serum transaminase increases * Nervous system disorders Common: headache * Gastrointestinal disorders Very Common: flatulence, constipation; Common: vomiting, diarrhea, dyspepsia, abdominal pain, stool abnormalities, nausea * Musculoskeletal and connective tissue disorders Uncommon: myalgia The background incidence of flatulence and diarrhea was the same in patients in controlled clinical trials, and higher in the placebo group. Only constipation and dyspepsia were shown to occur in a higher percentage of patients who received Cholestagel, compared to the placebo group. Side effects were generally mild or moderate in severity. In the application of<unk>  in combination with statins, no unexpected frequent side effects occurred.
Colesevelam
Tofisopam
Mitapivat
Orciprenaline
Nicorandil
Eluxadoline
Verapamil
Piribedil